Doximity Inc (DOCS.NYSE) AI FORECASTS & ADVISOR ANALYSIS

The base case accelerates as venture-backed AI competitors collapse under Doximity's predatory free pricing, granting the company an absolute monopoly over clinical documentation. Health systems begin mass-adopting the enterprise Clinical AI Suite, creating a massive, sticky SaaS revenue stream independent of volatile pharma marketing budgets.

• Competitor capitulation solidifies Doximity as the terminal physician OS.
• Enterprise SaaS contracts bypass the pharma-budget regulatory ceiling.
• Operating margins snap back to the mid-50s as AI compute costs achieve economies of scale.
• The multiple re-rates from a distressed value proxy to a premium AI healthcare platform.

The CFO's departure is revealed to be the tip of an accounting irregularity, triggering an SEC probe just as structural drug-pricing reforms permanently impair pharma marketing TAM. The 'AI investment year' proves to be a sunk-cost fallacy, with compute costs permanently destroying the historical 50% operating margins.

• Accounting investigations shatter institutional trust and halt the buyback program.
• TrumpRx permanently caps pharma ad spend, turning the 5% growth into negative growth.
• AI compute costs scale linearly rather than logarithmically, crushing FCF generation.
• The stock experiences severe multiple contraction down to a mid-single-digit P/E.

The consensus treats Doximity as a broken, ex-COVID growth darling that has hit a permanent wall. The media and sell-side analysts focus on the deceleration to 5% revenue growth in Q4 FY26, attributing it to irreversible pharma budget cuts under the TrumpRx regime. The narrative is heavily weighted by the recent EPS miss, the 'AI investment year' margin compression, and the sudden departure of the CFO, painting a picture of a company desperately pivoting to AI while its core advertising business decays.

The variant perception lies in the misdiagnosis of the margin compression. The crowd sees structural decay; I see an aggressive, cash-funded moat-building exercise. By absorbing the compute costs to offer ambient AI scribing for free, Doximity is starving venture-backed competitors and locking up the physician network. Furthermore, the governance red flag of the CFO's exit is forensically neutralized by the undeniable reality of the balance sheet: you cannot fake $317M in trailing free cash flow while simultaneously executing a $500M open-market buyback. The market is pricing DOCS for terminal decline, ignoring a pristine 7.5% FCF yield.

The convergence will trigger in late 2026/early 2027 (Q3/Q4 FY27 earnings) when pharmaceutical budgets unfreeze for the new calendar year. The combination of normalized pharma ad spend, initial monetization metrics from AI Search, and the mathematically accretive impact of the $500M buyback will force a violent upward repricing.